{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:31:24Z","timestamp":1791599484813,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"P3MI Bandung Institute of Technology","award":["2019"],"award-info":[{"award-number":["2019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 2 (VEGFR2) play an important role in cancer growth. Both of them have close relationships. Expression of EGFR will induce an angiogenic factor (VEGF) release for binding with VEGFR2. However, the existence of VEGF up-regulation independent of EGFR leads to cancer cell resistance to anti-EGFR. Therefore, a therapeutic approach targeting EGFR and VEGFR2 simultaneously may improve the outcome of cancer treatment. The present study was designed to identify potential compounds as a dual inhibitor of EGFR and VEGFR2 by the computational method. Firstly, the ligand-based pharmacophore model for each target was setup to screen of ZINC database of purchasable compounds. The hit compounds obtained by pharmacophore screening were then further screened by molecular docking studies. Taking erlotinib (EGFR inhibitor) and axitinib (VEGFR2 inhibitor) as reference drugs, six potential compounds (ZINC08398597, ZINC12047553, ZINC16525481, ZINC17418102, ZINC21942954, and ZINC38484632) were selected based on their docking scores and binding interaction. However, molecular dynamics simulations demonstrated that only ZINC16525481 and ZINC38484632 which have good binding free energy and stable hydrogen bonding interactions with EGFR and VEGFR2. The result represents a promising starting point for developing potent dual tyrosine kinases inhibitor of EGFR and VEGFR2.<\/jats:p>","DOI":"10.3390\/ijms21207779","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T10:14:22Z","timestamp":1603275262000},"page":"7779","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2"],"prefix":"10.3390","volume":"21","author":[{"given":"Frangky","family":"Sangande","sequence":"first","affiliation":[{"name":"School of Pharmacy, Bandung Institute of Technology, Jalan Ganesha 10, Bandung 40132, Indonesia"},{"name":"Study Program of Pharmacy, Faculty of Science and Technology, Universitas Prisma, Jalan Pomorow 113, Manado 95126, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Julianti","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Bandung Institute of Technology, Jalan Ganesha 10, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-0134","authenticated-orcid":false,"given":"Daryono Hadi","family":"Tjahjono","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Bandung Institute of Technology, Jalan Ganesha 10, Bandung 40132, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: Multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"Harari","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: A review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomaterials"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1634\/theoncologist.2008-0276","article-title":"Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC","volume":"14","author":"Pennell","year":"2009","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.apsb.2015.07.001","article-title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors","volume":"5","author":"Huang","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: Implications for combining Anti-VEGF and Anti-EGFR Agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"592","DOI":"10.4161\/cbt.9.8.11103","article-title":"ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK\/ERK and AKT\/PI3-K and induces apoptosis in breast cancer cells","volume":"9","author":"Sarkar","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s12325-013-0069-5","article-title":"Vandetanib in advanced medullary thyroid cancer: Review of adverse event management strategies","volume":"30","author":"Grande","year":"2013","journal-title":"Adv. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2013.10.058","article-title":"Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors","volume":"71","author":"Barbosa","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmech.2015.12.032","article-title":"Design and discovery of 4-anilinoquinazoline-acylamino derivatives as EGFR and VEGFR-2 dual TK inhibitors","volume":"109","author":"Zhang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1016\/j.bmc.2011.06.022","article-title":"Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors","volume":"19","author":"Li","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejmech.2016.07.049","article-title":"Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity","volume":"123","author":"Amin","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/1062936X.2010.548830","article-title":"Pharmacophore modelling, molecular docking and virtual screening for EGFR (HER 1) tyrosine kinase inhibitors","volume":"22","author":"Gupta","year":"2011","journal-title":"SAR QSAR Environ. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1016\/j.bmcl.2012.04.092","article-title":"Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screening","volume":"22","author":"Li","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.ejmech.2010.09.002","article-title":"Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors","volume":"45","author":"Lee","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15994","DOI":"10.3390\/ijms150915994","article-title":"In silico discovery of potential VEGFR-2 inhibitors from natural derivatives for anti-angiogenesis therapy","volume":"15","author":"Li","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/ci800293n","article-title":"Validation of molecular docking programs for virtual screening against dihydropteroate synthase","volume":"49","author":"Hevener","year":"2009","journal-title":"J. Chem. Inf. Model."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hosmer, D.W., Lemeshow, S., and Sturdivant, R.X. (2013). Applied Logistic Regression, John Wiley & Sons, Inc.. [3rd ed.].","DOI":"10.1002\/9781118548387"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4103\/1735-5362.245963","article-title":"Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of in-silico and in-vitro cytotoxicity methods","volume":"13","author":"Nasab","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.3390\/molecules19056368","article-title":"Synthesis, molecular docking and biological evaluation of Glycyrrhizin analogs as anticancer agents targeting EGFR","volume":"19","author":"Yang","year":"2014","journal-title":"Molecules"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1021\/jm400072p","article-title":"Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: The role of the DFG motif in the design of epidermal growth factor receptor inhibitors","volume":"56","author":"Peng","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.bmcl.2013.03.042","article-title":"Novel VEGFR-2 kinase inhibitors identified by the back-to-front approach","volume":"23","author":"Sanphanya","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_25","first-page":"2998","article-title":"Selecting protein structure\/s for docking-based virtual screening: A case study on type II inhibitors of VEGFR-2 Kinase","volume":"10","author":"Structures","year":"2019","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1016\/j.bmcl.2011.09.093","article-title":"Molecular dynamics simulations and MM\/GBSA methods to investigate binding mechanisms of aminomethylpyrimidine inhibitors with DPP-IV","volume":"21","author":"Desheng","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1021\/ci400429g","article-title":"An integrated virtual screening approach for VEGFR-2 inhibitors","volume":"53","author":"Zhang","year":"2013","journal-title":"J. Chem. Inf. Model."},{"key":"ref_28","first-page":"1010","article-title":"HyperChem: A software package for computational chemistry and molecular modeling","volume":"14","author":"Froimowitz","year":"1993","journal-title":"Biotechniques"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1021\/ci049885e","article-title":"LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters","volume":"45","author":"Wolber","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1021\/jm300687e","article-title":"Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking","volume":"55","author":"Mysinger","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/nar\/gks378","article-title":"ZINCPharmer: Pharmacophore search of the ZINC database","volume":"40","author":"Koes","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/ci049714+","article-title":"ZINC-A free database of commercially available compounds for virtual screening","volume":"45","author":"Irwin","year":"2005","journal-title":"J. Chem. Inf. Model."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/jcc.23905","article-title":"DOCK 6: Impact of new features and current docking performance","volume":"36","author":"Allen","year":"2015","journal-title":"J. Comput. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/prot.20035","article-title":"GEMDOCK: A Generic Evolutionary Method for Molecular Docking","volume":"55","author":"Yang","year":"2004","journal-title":"Proteins"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: Homology modeling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera-A visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1021\/acs.jctc.8b00768","article-title":"Automated Topology Builder Version 3.0: Prediction of Solvation Free Enthalpies in Water and Hexane","volume":"14","author":"Stroet","year":"2018","journal-title":"J. Chem. Theory Comput."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/ct700301q","article-title":"GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation","volume":"4","author":"Hess","year":"2008","journal-title":"J. Chem. Theory Comput."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g-mmpbsa-A GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7779\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:25:07Z","timestamp":1760178307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":39,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21207779"],"URL":"https:\/\/doi.org\/10.3390\/ijms21207779","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]}}}